Archives
-
SP600125: Translating JNK Signals into Inflammation Insight
2026-09-08
A mechanistic and translational framework for using SP600125 to interrogate JNK-dependent cytokine signaling, with emphasis on the TLR2/TLR4–MyD88–MAPK axis activated by Chlamydia psittaci CPSIT_0844.
-
1-myristoylglycerophosphocholine Assay Workflows
2026-09-07
Build defined 14:0 Lyso-PC experiments for fibroblast activation, epithelial lipid transfer, and smooth muscle function. This workflow combines species-resolved lipidomics, concentration-response design, and practical handling controls to improve reproducibility across lipid signaling and fibrosis models.
-
HA-LNP PTEN mRNA for Transdermal Melanoma Therapy
2026-09-07
This study develops a hyaluronate-conjugated lipid nanoparticle that delivers PTEN mRNA through the skin and targets CD44-expressing melanoma cells. Its findings connect transient tumor suppressor restoration with immunogenic cell death, tumor growth inhibition, and local immune activation, while highlighting the formulation challenges that shape transdermal mRNA therapy.
-
Gramine–CUL3–MTDH Ferroptosis in TNBC
2026-09-05
A 2026 study identifies gramine as a selective inhibitor of triple-negative breast cancer and links its activity to a previously described CUL3–MTDH regulatory route that promotes ferroptosis. By combining chemical screening, target-engagement assays, genetic perturbation, and xenograft models, the work provides a mechanistic framework for evaluating gramine while leaving important translational questions unresolved.
-
DAMGO as a Circuit Tool in Opioid Pain Research
2026-09-04
DAMGO is a selective µ-opioid receptor agonist that connects receptor-proximal pharmacology with circuit-level studies of opioid-induced mechanical hypersensitivity. This article presents an assay framework for interpreting DAMGO across signaling, tissue, and chronic pain research models.
-
Cell Counting Kit-8 for Melanoma Cell Studies
2026-09-04
Use Cell Counting Kit-8 to quantify melanoma cell growth, treatment response, and viability without a solubilization step. This practical workflow translates HSPA4 melanoma research into controlled, plate-based experiments with clear optimization and troubleshooting guidance.
-
Obeticholic Acid: Rethinking Fibrosis Translation
2026-09-03
Obeticholic Acid offers a mechanistically distinct route into liver fibrosis research by coupling FXR-driven bile acid homeostasis with metabolic, inflammatory, and vascular readouts. This thought-leadership analysis positions 6alpha-ethyl-chenodeoxycholic acid alongside emerging 11β-HSD1 biology and proposes a translational workflow for connecting molecular activation to tissue-level outcomes.
-
PCMT1 Drives Ovarian Cancer Metastasis
2026-09-03
Zhang et al. used a genome-wide CRISPR/Cas9 screen to identify PCMT1 as a functional driver of anoikis resistance and ovarian cancer dissemination. The study connects extracellular PCMT1 with LAMB3-integrin-FAK-Src signaling, providing a mechanistic explanation for effects on adhesion, invasion, ascites, and distant metastasis.
-
GM 6001 (Galardin) for ECM Research
2026-09-02
GM 6001 (Galardin) gives researchers broad MMP control for matrix remodeling, neural perineuronal-net studies, signaling assays, and tissue repair models. This workflow-focused guide explains how to formulate, dose, validate, and troubleshoot the inhibitor without confusing broad pathway suppression with isoform-specific causality.
-
Adenosine Triphosphate for Mitochondrial Assays
2026-09-02
Use ATP as a controlled energy and signaling variable to dissect OGDH regulation, mitochondrial proteostasis, and purinergic receptor signaling. This workflow-focused guide shows how ATP can complement the TCAIM study while providing practical preparation, dosing, controls, and troubleshooting strategies.
-
Galectin-1–FIP200 Axis in Hepatic Steatosis
2026-09-01
A 2026 study identifies galectin-1 as a causal suppressor of hepatic autophagy rather than merely a correlate of fatty liver disease. By combining mouse models, proteomics, protein-interaction analysis, structural mapping, and interaction-disrupting mutations, the work defines the Gal-1–FIP200 axis as a mechanistic link between autophagy blockade, steatosis, dyslipidemia, and insulin resistance.
-
Epigenetic Mcl-1 Targeting in Glioblastoma
2026-09-01
The reference study identifies a super-enhancer at the Mcl-1 locus as a glioblastoma vulnerability and shows that its disruption with THZ1 sensitizes tumors to BCL-2/BCL-XL inhibition. The resulting mitochondrial apoptosis and tumor-growth suppression support a synthetic-lethal strategy, while also highlighting the limits of translating model-system findings directly to patients.
-
Tropifexor (LJN452) Improves Neonatal Gut Barrier
2026-08-31
This open-access FASEB Journal study shows that FXR activation with Tropifexor reduces parenteral nutrition-associated intestinal injury in neonatal minipigs and strengthens epithelial defense responses. Transcriptomics and pediatric patient-derived organoids connect the in vivo phenotype to EPCAM-associated barrier regulation, providing a useful translational framework for intestinal and PN-related research.
-
MPP7, EMT, and Polarity in Ovarian Cancer
2026-08-31
The reference study identifies MPP7 as an overexpressed polarity-associated protein linked to poor prognosis in epithelial ovarian cancer. Through database analysis, tissue immunohistochemistry, MPP7 interference, functional assays, polarity imaging, transcriptomics, and immunoblotting, the authors connect MPP7 with EMT-related progression through Wnt/β-catenin signaling.
-
Catalpol in Alzheimer’s Disease: Mechanisms and Evidence
2026-08-30
The 2022 reference review synthesizes preclinical evidence that catalpol, an iridoid glycoside from Rehmannia glutinosa, may address several Alzheimer’s disease mechanisms, including neuroinflammation, oxidative stress, mitochondrial dysfunction, and neuronal apoptosis. Its main contribution is an integrated, multitarget interpretation of catalpol’s neuroprotective effects while also highlighting the limits of translating heterogeneous experimental findings into clinical treatment.